SCHEMBL356277

SCHEMBL356277

CCCn1nnc(N2CCC(n3cc(F)c4c(Cl)ncnc43)CC2)n1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.32
MEN1 O00255 3/20 0.32
EIF2AK3 Q9NZJ5 3/20 0.31
SCD O00767 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
RIPK2 O43353 3/20 0.31
SRC P12931 3/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
PDGFRB P09619 1/20 0.30
KIT P10721 1/20 0.30
FLT3 P36888 1/20 0.30
SIK1 P57059 1/20 0.30
RIPK4 P57078 1/20 0.30
DDR1 Q08345 1/20 0.30
RIPK1 Q13546 1/20 0.30
DSTYK Q6XUX3 1/20 0.30
RIPK3 Q9Y572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL356620 0.79 GPR119 (0.45) GPR119MEN1KMT2ANPC1RAB9A
SCHEMBL354786 0.79 GPR119 (0.40) GPR119
SCHEMBL10140747 0.78 MALT1 (0.37) MEN1ALDH1A1KMT2ARIPK2SRC
SCHEMBL357038 0.77 RIPK2 (0.38) GPR119MEN1EIF2AK3SCDKMT2A
SCHEMBL354783 0.77 RIPK2 (0.35) GPR119MEN1RIPK2SRCPDGFRB
SCHEMBL358364 0.77 GPR119 (0.36) GPR119RIPK2SRCPDGFRBKIT
SCHEMBL355724 0.77 GPR119 (0.40) GPR119MEN1KMT2ARIPK2SRC
SCHEMBL10172707 0.77 GPR119 (0.42) GPR119
Hydrochloric Acid SCHEMBL355732 0.76 GPR119 (0.41) GPR119
SCHEMBL10140674 0.76 ADK (0.34) EIF2AK3RIPK2SRCPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885MEN1 4883/4885EIF2AK3 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.